What is Intelligent Bio Solutions Inc's earnings per share (EPS)?

Intelligent Bio Solutions Inc (INBS) reported diluted earnings per share of $-2.00 for fiscal year 2025. This represents a 68.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Intelligent Bio Solutions Inc Financials

INBS

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE June

This page shows Intelligent Bio Solutions Inc (INBS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI INBS FY2025 2026-05-13

Persistent cash burn is the core business mechanic, with financing repeatedly filling the gap left by a subscale revenue base.

FY2025's balance-sheet pressure came from persistent operating burn, not from heavy debt service or capex: even after $4.6M of financing inflow, cash ended at only $1.0M. Because operating cash outflow barely improved from FY2024 while the current ratio fell below 1.0x, new capital is still acting as day-to-day fuel rather than a reserve, tying the reported loss directly to tighter short-term liquidity.

Unit economics improved from the FY2023 trough, because FY2025 gross margin remained above that earlier level even with revenue stuck near $3.1M. But overhead absorption is still weak: selling and admin expense of $8.9M dwarfs the gross profit pool, so better margin per sale has not translated into a meaningfully smaller operating loss.

Capital intensity is low: free cash outflow of $9.9M was almost the same as operating cash outflow of $9.7M. With capex only $232K, cash consumption comes from operations rather than expansion spending, so the operating model itself, at current scale, is what keeps shrinking liquidity.

Financial Health Signals

Financial Health Score 28/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Intelligent Bio Solutions Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

Revenue Progress

Burn Trend

Balance Sheet

Altman Z-Score Distress

-14.10

Intelligent Bio Solutions Inc scores -14.10, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($5.2M) relative to total liabilities ($5.4M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

2/8

Intelligent Bio Solutions Inc passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.92x

For every $1 of reported earnings, Intelligent Bio Solutions Inc generates $0.92 in operating cash flow (-$9.7M OCF vs -$10.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-174.8x

Intelligent Bio Solutions Inc earns $-174.8 in operating income for every $1 of interest expense (-$10.6M vs $61K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$3.1M

YoY-1.9%

5Y CAGR+74.5%

Intelligent Bio Solutions Inc generated $3.1M in revenue in fiscal year 2025. This represents a decrease of 1.9% from the prior year.

EBITDA

-$9.7M

YoY-3.9%

Intelligent Bio Solutions Inc's EBITDA was -$9.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 3.9% from the prior year.

Net Income

-$10.6M

YoY-4.1%

Intelligent Bio Solutions Inc reported -$10.6M in net income in fiscal year 2025. This represents a decrease of 4.1% from the prior year.

EPS (Diluted)

$-2.00

YoY+68.7%

Intelligent Bio Solutions Inc earned $-2.00 per diluted share (EPS) in fiscal year 2025. This represents an increase of 68.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$9.9M

YoY-1.2%

Intelligent Bio Solutions Inc generated -$9.9M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 1.2% from the prior year.

Cash & Debt

$1.0M

YoY-83.8%

5Y CAGR+19.0%

Intelligent Bio Solutions Inc held $1.0M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY+159.8%

Intelligent Bio Solutions Inc had 9M shares outstanding in fiscal year 2025. This represents an increase of 159.8% from the prior year.

Margins & Returns

Gross Margin

40.8%

YoY-5.0pp

Intelligent Bio Solutions Inc's gross margin was 40.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 5.0 percentage points from the prior year.

Operating Margin

-348.7%

YoY-18.2pp

5Y CAGR+1165.0pp

Intelligent Bio Solutions Inc's operating margin was -348.7% in fiscal year 2025, reflecting core business profitability. This is down 18.2 percentage points from the prior year.

Net Margin

-346.2%

YoY-19.8pp

5Y CAGR+1330.0pp

Intelligent Bio Solutions Inc's net profit margin was -346.2% in fiscal year 2025, showing the share of revenue converted to profit. This is down 19.8 percentage points from the prior year.

Return on Equity

-352.8%

YoY-230.8pp

Intelligent Bio Solutions Inc's ROE was -352.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 230.8 percentage points from the prior year.

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

$232K

YoY+4.7%

Intelligent Bio Solutions Inc invested $232K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 4.7% from the prior year.

INBS Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$3.1M-1.9%	$3.1M+147.6%	$1.3M+187.5%	$437K-77.9%	$2.0M+949.3%	$189K
Cost of Revenue	$1.8M+7.1%	$1.7M+81.3%	$930K	N/A	N/A	N/A
Gross Profit	$1.2M-12.5%	$1.4M+336.4%	$327K	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$8.9M-4.0%	$9.3M+15.3%	$8.0M+63.1%	$4.9M+46.5%	$3.4M+52.5%	$2.2M
Operating Income	-$10.6M-3.5%	-$10.3M+18.4%	-$12.6M-51.1%	-$8.3M-49.6%	-$5.6M-95.1%	-$2.9M
Interest Expense	$61K-63.6%	$167K	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$10.6M-4.1%	-$10.2M+4.5%	-$10.6M-28.0%	-$8.3M-18.0%	-$7.0M-122.4%	-$3.2M
EPS (Diluted)	$-2.00+68.7%	$-6.38	$-127.00	$-11.33	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Revenue	$1.1M+18.3%	$897K-19.3%	$1.1M+170.6%	$411K-54.5%	$902K+21.7%	$741K-25.8%	$998K+162.1%	$381K
Cost of Revenue	$525K+20.2%	$437K-26.4%	$594K+16.8%	$508K+31.2%	$387K+0.8%	$384K-26.9%	$525K+699.0%	-$88K
Gross Profit	$535K+16.5%	$460K-11.3%	$518K+631.8%	-$97K-128.6%	$341K+53.0%	$223K-35.7%	$347K-57.5%	$816K
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$2.5M+5.2%	$2.3M-12.1%	$2.7M-1.9%	$2.7M+12.3%	$2.4M+33.5%	$1.8M-7.2%	$1.9M-27.0%	$2.7M
Operating Income	-$2.9M-11.8%	-$2.6M+12.1%	-$3.0M+3.1%	-$3.1M-20.9%	-$2.6M-13.1%	-$2.3M+16.9%	-$2.7M+3.1%	-$2.8M
Interest Expense	$4K-92.5%	$56K+1340.1%	$4K-77.2%	$17K+116.5%	$8K-41.3%	$14K-39.5%	$22K-59.1%	$55K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$2.9M-6.9%	-$2.7M+10.2%	-$3.0M+3.5%	-$3.1M-21.5%	-$2.5M-13.1%	-$2.2M+16.2%	-$2.7M+3.5%	-$2.8M
EPS (Diluted)	$-1.80+36.2%	$-2.82	$-0.35	N/A	$-4.41+11.1%	$-4.96-608.6%	$-0.70	N/A

INBS Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$8.2M-40.1%	$13.8M+33.1%	$10.4M-16.2%	$12.4M-43.5%	$21.9M+783.0%	$2.5M
Current Assets	$4.1M-51.5%	$8.5M+120.9%	$3.9M-64.5%	$10.9M-40.3%	$18.2M+678.1%	$2.3M
Cash & Equivalents	$1.0M-83.8%	$6.3M+310.1%	$1.5M-81.3%	$8.2M-34.5%	$12.6M+2842.8%	$427K
Inventory	$635K-18.3%	$778K-20.7%	$980K	N/A	N/A	N/A
Accounts Receivable	$595K+38.4%	$430K+46.2%	$294K	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$5.4M-2.9%	$5.6M-16.1%	$6.7M+14.8%	$5.8M-15.3%	$6.9M-10.9%	$7.7M
Current Liabilities	$5.4M-1.8%	$5.5M-7.4%	$5.9M+26.2%	$4.7M+26.6%	$3.7M-52.1%	$7.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$3.0M-64.0%	$8.3M+119.3%	$3.8M-42.7%	$6.6M-56.0%	$15.1M+390.3%	-$5.2M
Retained Earnings	-$62.5M-20.3%	-$52.0M-24.3%	-$41.8M-34.1%	-$31.2M-36.3%	-$22.9M-44.4%	-$15.8M

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Total Assets	$14.9M-15.8%	$17.7M+75.9%	$10.0M+21.7%	$8.2M-13.9%	$9.6M+10.4%	$8.7M-25.9%	$11.7M-14.9%	$13.8M
Current Assets	$9.7M-19.9%	$12.2M+171.5%	$4.5M+8.4%	$4.1M-19.0%	$5.1M+25.7%	$4.1M-37.3%	$6.5M-24.1%	$8.5M
Cash & Equivalents	$6.9M+826.9%	$740K-55.4%	$1.7M+62.8%	$1.0M-63.7%	$2.8M+25.2%	$2.2M-43.8%	$4.0M-36.7%	$6.3M
Inventory	$597K+1.2%	$590K-6.0%	$628K-1.1%	$635K-7.1%	$683K-2.5%	$701K-5.1%	$739K-5.0%	$778K
Accounts Receivable	$878K+92.3%	$457K-36.4%	$718K+20.7%	$595K+16.4%	$511K+92.0%	$266K-54.0%	$579K+34.6%	$430K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$6.1M-9.6%	$6.8M+2.3%	$6.6M+21.6%	$5.4M+17.1%	$4.6M+3.6%	$4.5M-22.4%	$5.8M+3.2%	$5.6M
Current Liabilities	$4.6M-10.1%	$5.1M+1.3%	$5.1M-5.4%	$5.4M+17.2%	$4.6M+3.7%	$4.4M-22.5%	$5.7M+4.2%	$5.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$9.0M-19.2%	$11.1M+206.3%	$3.6M+20.9%	$3.0M-41.4%	$5.1M+17.1%	$4.4M-28.5%	$6.1M-26.7%	$8.3M
Retained Earnings	-$71.1M-4.2%	-$68.2M-4.1%	-$65.5M-4.8%	-$62.5M-5.2%	-$59.4M-4.5%	-$56.9M-4.1%	-$54.6M-5.2%	-$52.0M

INBS Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$9.7M-1.1%	-$9.6M-29.7%	-$7.4M-119.7%	-$3.4M+70.3%	-$11.3M-2165.6%	-$499K
Capital Expenditures	$232K+4.7%	$221K	N/A	N/A	N/A	N/A
Free Cash Flow	-$9.9M-1.2%	-$9.8M	N/A	N/A	N/A	N/A
Investing Cash Flow	-$232K-4.7%	-$221K+68.1%	-$694K+21.1%	-$880K	N/A	-$14K
Financing Cash Flow	$4.6M-68.4%	$14.6M+914.4%	$1.4M	N/A	$23.4M+3089.0%	$734K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Operating Cash Flow	-$4.3M-176.3%	-$1.6M+44.9%	-$2.8M-28.8%	-$2.2M+19.8%	-$2.8M-18.5%	-$2.3M+2.6%	-$2.4M+18.9%	-$2.9M
Capital Expenditures	-$13K-118.9%	$68K-3.1%	$70K	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	-$4.3M-165.5%	-$1.6M+43.9%	-$2.9M	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$13K+146.0%	-$28K+60.1%	-$70K+66.2%	-$209K-1349.5%	-$14K	N/A	N/A	-$167K
Financing Cash Flow	$10.4M+1447.3%	$675K-81.0%	$3.6M+491.1%	$602K-81.9%	$3.3M+425.8%	$632K+1388.2%	$42K+699.0%	$5K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

INBS Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	40.8%-5.0pp	45.8%+19.8pp	26.0%	N/A	N/A	N/A
Operating Margin	-348.7%-18.2pp	-330.5%+671.6pp	-1002.1%+905.0pp	-1907.1%-1625.7pp	-281.4%+1232.3pp	-1513.7%
Net Margin	-346.2%-19.8pp	-326.4%+519.5pp	-845.9%+1054.2pp	-1900.1%-1544.7pp	-355.3%+1320.9pp	-1676.2%
Return on Equity	-352.8%-230.8pp	-121.9%+157.9pp	-279.9%-154.5pp	-125.4%-78.6pp	-46.7%	N/A
Return on Assets	-128.1%-54.4pp	-73.7%+29.0pp	-102.7%-35.4pp	-67.2%-35.0pp	-32.2%+95.6pp	-127.8%
Current Ratio	0.77-0.8	1.57+0.9	0.66-1.7	2.33-2.6	4.94+4.6	0.30
Debt-to-Equity	1.81+1.1	0.67-1.1	1.76+0.9	0.88+0.4	0.46+1.9	-1.48
FCF Margin	-324.6%-9.9pp	-314.7%	N/A	N/A	N/A	N/A

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Gross Margin	50.5%-0.8pp	51.3%+4.7pp	46.6%+70.3pp	-23.7%-61.6pp	37.8%+7.7pp	30.1%-4.6pp	34.7%-179.4pp	214.1%
Operating Margin	-277.8%+16.1pp	-293.9%-24.1pp	-269.8%+483.4pp	-753.2%-469.4pp	-283.8%+21.7pp	-305.5%-32.6pp	-273.0%+465.2pp	-738.2%
Net Margin	-269.9%+28.7pp	-298.6%-30.3pp	-268.3%+483.8pp	-752.1%-470.2pp	-281.9%+21.6pp	-303.5%-34.5pp	-269.0%+462.0pp	-731.0%
Return on Equity	-31.9%-7.8pp	-24.1%+58.2pp	-82.4%+20.8pp	-103.1%-53.4pp	-49.7%+1.8pp	-51.5%-7.5pp	-44.0%-10.6pp	-33.4%
Return on Assets	-19.3%-4.1pp	-15.2%+14.6pp	-29.7%+7.7pp	-37.5%-10.9pp	-26.5%-0.6pp	-25.9%-3.0pp	-22.9%-2.7pp	-20.2%
Current Ratio	2.11-0.3	2.37+1.5	0.89+0.1	0.77-0.3	1.12+0.2	0.92-0.2	1.14-0.4	1.57
Debt-to-Equity	0.68+0.1	0.61-1.2	1.83+0.0	1.81+0.9	0.91-0.1	1.03+0.1	0.95+0.3	0.67
FCF Margin	-409.4%-227.1pp	-182.4%+80.0pp	-262.4%	N/A	N/A	N/A	N/A	N/A

Note: The current ratio is below 1.0 (0.77), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Ainos Inc AIMD

$13.8M

Nexalin Tech NXL

$7.8M

ALLURION TECHNOLOGIES INC ALUR

$10.0M

Envveno Medical Corporation NVNO

$7.4M

Sintx Technologies Inc SINT

$11.8M

Frequently Asked Questions

What is Intelligent Bio Solutions Inc's annual revenue?

Intelligent Bio Solutions Inc (INBS) reported $3.1M in total revenue for fiscal year 2025. This represents a -1.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Intelligent Bio Solutions Inc's revenue growing?

Intelligent Bio Solutions Inc (INBS) revenue declined by 1.9% year-over-year, from $3.1M to $3.1M in fiscal year 2025.

Is Intelligent Bio Solutions Inc profitable?

No, Intelligent Bio Solutions Inc (INBS) reported a net income of -$10.6M in fiscal year 2025, with a net profit margin of -346.2%.

What is Intelligent Bio Solutions Inc's EBITDA?

Intelligent Bio Solutions Inc (INBS) had EBITDA of -$9.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Intelligent Bio Solutions Inc's gross margin?

Intelligent Bio Solutions Inc (INBS) had a gross margin of 40.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Intelligent Bio Solutions Inc's operating margin?

Intelligent Bio Solutions Inc (INBS) had an operating margin of -348.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Intelligent Bio Solutions Inc's net profit margin?

Intelligent Bio Solutions Inc (INBS) had a net profit margin of -346.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Intelligent Bio Solutions Inc's return on equity (ROE)?

Intelligent Bio Solutions Inc (INBS) has a return on equity of -352.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Intelligent Bio Solutions Inc's free cash flow?

Intelligent Bio Solutions Inc (INBS) generated -$9.9M in free cash flow during fiscal year 2025. This represents a -1.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Intelligent Bio Solutions Inc's operating cash flow?

Intelligent Bio Solutions Inc (INBS) generated -$9.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Intelligent Bio Solutions Inc's total assets?

Intelligent Bio Solutions Inc (INBS) had $8.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Intelligent Bio Solutions Inc's capital expenditures?

Intelligent Bio Solutions Inc (INBS) invested $232K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does Intelligent Bio Solutions Inc have outstanding?

Intelligent Bio Solutions Inc (INBS) had 9M shares outstanding as of fiscal year 2025.

What is Intelligent Bio Solutions Inc's current ratio?

Intelligent Bio Solutions Inc (INBS) had a current ratio of 0.77 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Intelligent Bio Solutions Inc's debt-to-equity ratio?

Intelligent Bio Solutions Inc (INBS) had a debt-to-equity ratio of 1.81 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Intelligent Bio Solutions Inc's return on assets (ROA)?

Intelligent Bio Solutions Inc (INBS) had a return on assets of -128.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Intelligent Bio Solutions Inc's cash runway?

Based on fiscal year 2025 data, Intelligent Bio Solutions Inc (INBS) had $1.0M in cash against an annual operating cash burn of $9.7M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Intelligent Bio Solutions Inc's Altman Z-Score?

Intelligent Bio Solutions Inc (INBS) has an Altman Z-Score of -14.10, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Intelligent Bio Solutions Inc's Piotroski F-Score?

Intelligent Bio Solutions Inc (INBS) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Intelligent Bio Solutions Inc's earnings high quality?

Intelligent Bio Solutions Inc (INBS) has an earnings quality ratio of 0.92x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Intelligent Bio Solutions Inc cover its interest payments?

Intelligent Bio Solutions Inc (INBS) has an interest coverage ratio of -174.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Intelligent Bio Solutions Inc?

Intelligent Bio Solutions Inc (INBS) scores 28 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.